NASDAQ:BIOS BioPlus Acquisition (BIOS) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free BIOS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.79▼$10.8050-Day Range$10.75▼$10.8452-Week Range$10.05▼$11.68Volume5,600 shsAverage Volume122,781 shsMarket Capitalization$209.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BioPlus Acquisition alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About BioPlus Acquisition Stock (NASDAQ:BIOS)BioPlus Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. BioPlus Acquisition Corp. was incorporated in 2021 and is based in New York, New York.Read More Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide BIOS Stock News HeadlinesApril 16, 2024 | markets.businessinsider.comImugene and Kincell Bio Announce Strategic Manufacturing and Process Development PartnershipApril 3, 2024 | benzinga.comLouis G Lange's Net WorthApril 27, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 9, 2024 | msn.comWhy Intelligent Bio Solutions Stock Is Ripping HigherJanuary 22, 2024 | investing.comBioPlus Co Ltd (099430)October 4, 2023 | msn.comSPAC BioPlus, Avertix terminate merger; BioPlus to liquidateOctober 4, 2023 | markets.businessinsider.comAvertix, BIOS Acquisition Agree To Terminate Merger DealOctober 4, 2023 | finance.yahoo.comAvertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business CombinationApril 27, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. October 4, 2023 | finance.yahoo.comBioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to LiquidateAugust 16, 2023 | finance.yahoo.comHeart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient MonitoringAugust 16, 2023 | finance.yahoo.comAvertix Partners with Institute on Implantable Heart Attack Detection SystemJuly 20, 2023 | finance.yahoo.comAvertix Medical Welcomes Renown Cardiologist to Board of DirectorsJuly 17, 2023 | finance.yahoo.comRenown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of DirectorsJune 13, 2023 | finance.yahoo.comAvertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth OrlandoMay 26, 2023 | seekingalpha.comBIOS BioPlus Acquisition Corp.May 5, 2023 | msn.comSPAC BIOS to merge with cardiac device maker AvertixMay 3, 2023 | finance.yahoo.comAvertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition CorporationMarch 18, 2023 | money.usnews.comBioPlus Acquisition Corp - Ordinary Shares - Class ASeptember 23, 2022 | wsj.comBioPlus Acquisition Corp. Cl ASeptember 20, 2022 | finance.yahoo.comBioPlus Acquisition Corp. (BIOS)September 3, 2022 | investing.comBioPlus Acquisition Corp (BIOS)August 13, 2022 | reuters.comBioPlus Acquisition CorpAugust 10, 2022 | finance.yahoo.comWhat Type Of Shareholders Own The Most Number of BioPlus Acquisition Corp. (NASDAQ:BIOS) Shares?See More Headlines Receive BIOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPlus Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorUnclassified Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:BIOS CUSIPN/A CIK1856653 Webbioplusspac.com Phone212-287-4092FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares19,370,000Free Float14,990,000Market Cap$209.20 million OptionableNot Optionable Beta0.01 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Jonathan M. N. Rigby MBA (Age 55)Chairman & Chief Bus. Officer Mr. R. Ross Haghighat (Age 59)CEO, CFO & Director Key CompetitorsRCF AcquisitionNYSE:RCFAHelix Acquisition Corp. IINASDAQ:HLXBEnphys AcquisitionNYSE:NFYSKeen Vision AcquisitionNASDAQ:KVACGores Holdings IXNASDAQ:GHIXView All Competitors BIOS Stock Analysis - Frequently Asked Questions When did BioPlus Acquisition IPO? BioPlus Acquisition (BIOS) raised $180 million in an initial public offering (IPO) on Friday, December 3rd 2021. The company issued 18,000,000 shares at $10.00 per share. Cantor acted as the underwriter for the IPO. This page (NASDAQ:BIOS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPlus Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
